2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Treatment Considerations, Supportive Care, Biological Therapies, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Diseases, Bleeding and Clotting, Thromboembolism, Thrombocytopenias, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, MPN, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult, Pediatric, Pregnant
PAPER

4854 Incidence, timing, and predictors of ischemic stroke and arterial thrombosis after cancer-associated venous thromboembolism

Elexis Price, MD, MPH, Laura Dodge2, Andrew Bueno, MD3, Ladan Kasraian, MD4, Vasiliki Xirou, MD5, Amalia Stavropoulos, M.B.B.S6, Cesar Burgos Jimenez, MD7, Deepa Rangachari, MD8, Caleb Shi9, Fernanda Maria De Queiroz Silva, MD10, Avi Leader, MD11, Aaron Shoskes, DO12, Rushad Patell, MD13
1 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
2 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
3 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
4 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
5 Mount Auburn Hospital, Cambridge, Massachusetts, United States
6 Mount Auburn Hospital, Cambridge, Massachusetts, United States
7 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
8 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
9 Northeastern University, Boston, Massachusetts, United States
10 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
11 Memorial Sloan Kettering Cancer Center, New York, New York, United States
12 University of Utah, Salt Lake City, Utah, United States
13 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Background:
Cancer-associated thrombosis (CAT) may identify a subgroup of patients at elevated risk for arterial thrombotic events (ATE), particularly ischemic stroke, despite therapeutic anticoagulation. We sought to determine the one-year cumulative incidence of ischemic stroke and overall ATE after CAT and to identify clinical factors associated with these events.

Methods: We conducted a retrospective cohort study of patients with CAT at Beth Israel Deaconess Medical Center between 2016 and 2021. The index date was the date of diagnosis of the qualifying VTE. Patients were followed from the index date until the first outcome event, death, last clinical follow-up, or one year. The primary outcome was ischemic stroke; the secondary outcome was overall ATE, defined as ischemic stroke, myocardial infarction, or other systemic arterial thrombosis. One-year cumulative incidence was estimated with death as a competing event. Multivariable Fine-Gray competing-risk regression was used to identify factors associated with ischemic stroke and overall ATE, adjusting for patient characteristics, cancer type and stage, anticancer therapy, cardiovascular comorbidities, baseline antiplatelet use, and initial post-VTE anticoagulant class.

Results: Among 616 patients with CAT, the mean age was 66.7 years and 325 (52.8%) were female. Most patients had metastatic disease (68.9%) and the most frequent cancer types were gastrointestinal (210, 34.2%), lung (130, 21.1%), and genitourinary (79, 12.9%). Hypertension was present in 61.9%, diabetes in 24.0%, heart failure in 10.9%, atrial fibrillation in 10.5%, and prior arterial thrombosis in 65 (10.6%) of whom 8 had experienced a stroke. At the time of index VTE, 28.5% were receiving antiplatelet therapy. The index event was pulmonary embolism (PE) alone in 70.6%, lower-extremity deep vein thrombosis (DVT) alone in 25.8%, and concurrent PE and DVT in 3.6%.  Initial post-VTE anticoagulation consisted of low-molecular-weight heparin (LMWH) in 49.8%, direct oral anticoagulant (DOAC) in 37.5%, and other agents in 12.7%. Median follow-up was 265.5 (IQR, 63.0-365.0) days, and 292 patients (47.4%) died within one year.

Within one year, 26 patients developed ischemic stroke, corresponding to a cumulative incidence of 4.2% (95% CI, 2.8%–6.1%); the median time from VTE to stroke was 24 days (IQR, 7–111). Of these, 21 (80.8%) strokes were symptomatic. Notably, eight of the 26 (30.8%) patients with stroke had anticoagulation held in the days prior to their stroke. Overall ATE occurred in 39 patients, with a cumulative incidence of 6.3% (95% CI, 4.5%–8.6%) and a median time to event of 21 days (IQR, 5–82). Nonexclusive event subtypes included: ischemic stroke (n=26), splanchnic arterial thrombosis (n=8), myocardial infarction (n=2), peripheral arterial thrombosis (n=2), aortic thrombosis (n=1), and other ATE (n=2).

In adjusted Fine-Gray models, metastatic disease (sHR, 4.54; 95% CI, 3.21–6.42), gastrointestinal cancer (sHR, 2.02; 95% CI, 1.09–3.73), and lung cancer (sHR, 1.96; 95% CI, 1.04–3.69) were associated with increased ischemic stroke risk. Metastatic disease (sHR, 4.17; 95% CI, 2.97–5.86) and gastrointestinal cancer (sHR, 2.26; 95% CI, 1.23–4.16) were also associated with increased risk of overall ATE. Notably, traditional cardiovascular comorbidities such as hypertension,  hyperlipidemia and prior arterial thrombosis were not independently associated with either outcome. Moreover, the anticoagulant class selected after the index VTE was also not associated with the risk of ischemic stroke (DOAC vs LMWH: sHR, 1.02; 95% CI, 0.76–1.36) or overall ATE (sHR, 0.95; 95% CI, 0.71–1.28).

Conclusion: ATE, particularly ischemic stroke, occurred frequently and early after CAT and disproportionately affected patients with metastatic disease, gastrointestinal cancer, and lung cancer. The absence of an independent association with traditional cardiovascular risk factors or anticoagulant class suggests that cancer-related factors may be central to this risk. These findings identify a period of heightened thrombotic vulnerability after CAT and may inform risk stratification, closer surveillance, and future studies of preventive strategies in high-risk patients.

Elexis Price, MD, MPH: No relevant conflicts of interest to declare.